BioCentury
ARTICLE | Finance

Maintaining Moderna

How Hong Kong listing could help Moderna secure its $7B valuation

April 2, 2018 4:51 PM UTC

A rumored dual listing on the Hong Kong stock exchange and NASDAQ could enable Moderna Therapeutics Inc. to maintain its ballooning valuation as it enters the public market.

The mRNA play has raised $1.6 billion in private funding, and following its $500 million series G round in February, CFO Lorence Kim confirmed the company’s valuation “is close to $7 billion.”...

BCIQ Company Profiles

Moderna Inc.